Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.57 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041842 | 0.96 | LGALS3 (0.62) | LGALS3LGALS1 | |
| SCHEMBL23041845 | 0.96 | LGALS3 (0.62) | LGALS3LGALS1 | |
| SCHEMBL26977921 | 0.96 | LGALS3 (0.62) | LGALS3LGALS1 | |
| SCHEMBL26977609 | 0.93 | LGALS3 (0.61) | LGALS3LGALS1 | |
| SCHEMBL23041788 | 0.93 | LGALS3 (0.60) | LGALS3LGALS1 | |
| SCHEMBL26977486 | 0.89 | LGALS3 (0.49) | LGALS3LGALS1 | |
| SCHEMBL28755683 | 0.86 | LGALS3 (0.47) | LGALS3LGALS1 | |
| SCHEMBL26977364 | 0.86 | LGALS3 (0.55) | LGALS3LGALS1 | |
| SCHEMBL23041820 | 0.84 | LGALS3 (0.62) | LGALS3LGALS1 | |
| SCHEMBL26977426 | 0.83 | LGALS3 (0.49) | LGALS3LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021904-B1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-03 | — | — | EP | claimed |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-08 | — | — | US | claimed |
| EP-4021904-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-07-06 | — | — | EP | claimed |
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-03 | — | — | US | disclosed |
| EP-4021904-B1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-08 | — | — | US | disclosed |
| EP-4021904-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021038068-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257056-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885 |
| US-20220281855-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885 |
| US-12319672-B2 | Alpha-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.